LC
Lineage Cell Therapeutics, Inc.
LCTX · AMEX
$1.02 -0.97% (-$0.01)
1M -4.63%
Market Cap $258.0M
P/E Ratio -
Div. Yield -
ROE 71.14%
Piotroski F-Score Weak
3/9Valuation
24 /100
Expensive P/S 19.72x
P/B 4.24x
P/E N/A
Growth
14 /100
Declining Rev. growth 0.33%
Book val. growth 15.31%
EPS growth N/A
Profitability
20 /100
Weak Gross margin 96.59%
Net margin 246.58%
Op. margin 205.23%
Quality
2 /100
Poor ROIC 23.25%
ROE 71.14%
ROA 30.37%
Debt
100 /100
Low Debt/Equity 0.04x
Current ratio 6.61x
Int. coverage N/A
Stability
8 /100
Unstable Beta 1.55x
Rev. volatility 46.20%
EPS volatility 128.37%
Bulios Scoring popisuje kvalitu a minulost firmy, ne budoucí výnos. Vysoké skóre není nákupní signál. Zjistit více
Zeptejte se StockBota na LCTX
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Brian Culley
Employees
75
Headquarters
Carlsbad
Nadcházející události
05 LIS
Earnings
Upcoming earnings report